188844-34-0
188844-34-0
Chemical Structure
HX531
- CAS No.: 188844-34-0
- Formula:C29H29N3O4
- Molecular Weight:483.56
IUPAC Name: 4-(5,7,7,10,10-pentamethyl-2-nitro-7,8,9,10-tetrahydro-5H-benzo[b]naphtho[2,3-e][1,4]diazepin-12-yl)benzoic acid
InChIKey: SXKPGYKPQPYJER-UHFFFAOYSA-N
SMILES: O=C(O)C1=CC=C(C2=NC3=CC([N+]([O-])=O)=CC=C3N(C)C4=CC5=C(C(C)(C)CCC5(C)C)C=C42)C=C1
Biological Activity: HX531 is an orally active RXR antagonist with an IC50 of 18 nM. HX531 upregulates the p53-p21Cip1 pathway. HX531 abrogates the anti-apoptotic effect of t-RA. HX531 exerts anti-obesity, anti-diabetic and anti-melanoma activities[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
HX531 | 99.87% | HX531 is an orally active RXR antagonist with an IC50 of 18 nM. HX531 upregulates the p53-p21Cip1 pathway. HX531 abrogates the anti-apoptotic effect of t-RA. HX531 exerts anti-obesity, anti-diabetic and anti-melanoma activities. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
HX531 (Standard) | ≥98% | HX531 (Standard) is the analytical standard of HX531 (HY-108521). This product is intended for research and analytical applications. HX531 is an orally active RXR antagonist with an IC50 of 18 nM. HX531 upregulates the p53-p21Cip1 pathway. HX531 abrogates the anti-apoptotic effect of t-RA. HX531 exerts anti-obesity, anti-diabetic and anti-melanoma activities. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Konta T, et al. Selective roles of retinoic acid receptor and retinoid x receptor in the suppression of apoptosis by all-trans-retinoic acid. J Biol Chem. 2001 Apr 20;276(16):12697-701. [Content Brief]
- [2]. Yamauchi T, et al. Inhibition of RXR and PPARgamma ameliorates diet-induced obesity and type 2 diabetes. J Clin Invest. 2001 Oct;108(7):1001-13. [Content Brief]
- [3]. Atsuko Nakatsuka, et al. RXR antagonism induces G0 /G1 cell cycle arrest and ameliorates obesity by up-regulating the p53-p21(Cip1) pathway in adipocytes. J Pathol. 2012 Apr;226(5):784-95. [Content Brief]
